Second-line treatment after disease progression following first-line chemotherapy with modified FOLFIRINOX in advanced pancreatic cancer patients

被引：1
|
作者：
Vivaldi, C. [1 ]
Vasile, E. [1 ]
Fornaro, L. [1 ]
Caparello, C. [1 ]
Musettini, G. [1 ]
Pasquini, G. [1 ]
Lencioni, M. [2 ]
Ricci, S. [2 ]
Falcone, A. [1 ]
机构：
[1] Azienda Osped Univ Pisana, UO Oncol Med Univ 2, Pisa, Italy
[2] Azienda Osped Univ Pisana, UO Oncol Med Osped 1, Pisa, Italy
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)31278-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2362
引用
收藏
页码：S456 / S457
页数：2
相关论文
共 50 条
  • [31] Modified FOLFIRINOX as second-line therapy in 140 patients with pancreatic adenocarcinoma patients who have failed first-line treatment using gemcitabine and nab-paclitaxel
    Farrell, D.
    Fitzgerald, S.
    Daly, A.
    Knox, B.
    Divilly, J.
    Robinson, M.
    Gallagher, L.
    Burke, P.
    Dean, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S148 - S148
  • [32] CORRELATION BETWEEN THE EFFECTS OF FIRST-LINE CHEMOTHERAPY AND SURVIVAL TIME FROM SECOND-LINE CHEMOTHERAPY IN PATIENTS WITH ADVANCED GASTRIC CANCER
    Tabuse, H.
    Yasui, H.
    Funakoshi, T.
    Hamauchi, S.
    Tsushima, T.
    Taniguchi, H.
    Todaka, A.
    Yokota, T.
    Machida, N.
    Yamasaki, K.
    Fukutomi, A.
    Onozawa, Y.
    Boku, N.
    ANNALS OF ONCOLOGY, 2012, 23 : 99 - 99
  • [33] Skeletal Muscle Mass Predicts Poor Prognosis in Patients with Advanced Pancreatic Cancer Undergoing Second-Line FOLFIRINOX Chemotherapy
    Lee, Hee Seung
    Kim, Si Young
    Chung, Moon Jae
    Park, Jeong Youp
    Bang, Seungmin
    Park, Seung Woo
    Song, Si Young
    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2019, 71 (07): : 1100 - 1107
  • [34] Patient-tailored FOLFIRINOX in the first-line treatment of patients (pts) with advanced pancreatic cancer (PC).
    Ulusakarya, Ayhan
    Teyar, Nahla
    Karaboue, Abdoulaye
    Haydar, Mazen
    Krimi, Sarra
    Biondani, Pamela
    Gumus, Yusuf
    Almohamad, Watek
    Morere, Jean-Francois
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [35] FOLFIRINOX as a first-line chemotherapy for patients (pts) with advanced biliary tract cancer (BTC)
    Ulusakarya, A.
    Karray, W.
    Abdou, J.
    Karaboue, A.
    Haydar, M.
    Krimi, S.
    Gumus, Y.
    Almohamad, W.
    Goldschmidt, E.
    Biondani, P.
    Morere, J. F.
    ANNALS OF ONCOLOGY, 2018, 29 : 260 - 260
  • [36] Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure
    Kobayashi, Noritoshi
    Shimamura, Takeshi
    Tokuhisa, Motohiko
    Goto, Ayumu
    Endo, Itaru
    Ichikawa, Yasushi
    MEDICINE, 2017, 96 (19)
  • [37] Modified FOLFIRINOX as a second-line treatment in pancreatic adenocarcinoma patients with poor performance status.
    Das, Adarsh
    Dean, Andrew Peter
    Higgs, Domenic
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [38] Advanced bladder cancer: Status of first-line chemotherapy and the search for active agents in the second-line setting
    Gallagher, David J.
    Milowsky, Matthew I.
    Bajorin, Dean F.
    CANCER, 2008, 113 (06) : 1284 - 1293
  • [39] A randomized trial of FOLFIRI versus docetaxel and cisplatin as a second-line chemotherapy after failure of first-line chemotherapy in advanced gastric cancer
    Kil, Lee Sang
    Seok, Moon Hee
    Eun, Kim Sung
    Seok, Jang Jin
    Young, Cho Joo
    Sun, Kim Eun
    Hyung, Lee Si
    Chul, Park Jun
    Kang, Lee Yong
    ANNALS OF ONCOLOGY, 2017, 28
  • [40] Prognostic model for patients (pts) with advanced pancreatic cancer (aPC) receiving first-line modified FOLFIRINOX (mFOLFIRINOX)
    Vivaldi, C.
    Vasile, E.
    Fornaro, L.
    Pasquini, G.
    Catanese, S.
    Caparello, C.
    Musettini, G.
    Lencioni, M.
    Ricci, S.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2015, 26 : 95 - 95
12345